

3RD BOSTON RADIONUCLIDE THERANOSTICS FORUM

 Eckert & Ziegler
Contributing to saving lives

MAY 29TH, 2025
8:30AM TO 3PM

Morrison Foerster
200 Clarendon Street in Boston

THERANOSTICS IS COMING OF AGE IN PRECISION ONCOLOGY

ABOUT THIS FORUM

WHY THERANOSTICS?

Theranostics in nuclear medicine is an exciting and rapidly evolving field that offers enormous potential for personalized medicine. By mixing and matching diagnostic and therapeutic capabilities, theranostics allows physicians to tailor treatment plans to each individual patient based on their unique molecular characteristics. Recent FDA- and EMA-approvals of NET- and prostate cancer theranostics document that radionuclide theranostics is ready for prime time. The next years will show if radionuclide theranostics is indeed a new platform technology and live up to its expectations. (*adapted from Carrie Arnold, Nature Medicine 2022*)

WHY BOSTON ON MAY 29TH?

Boston **prior to ASCO** is the perfect location as it is representing a mix of outstanding science, world class clinical care and forward looking entrepreneurship.

Moreover, the intimate setup of this half day event will allow many informal discussions, hopefully leading to a playbook on how to establish radionuclide theranostics as a platform technology complementing established targeted oncology and immunotherapy.

GOAL OF THE FORUM

After two successful editions, we are pleased to invite you to the **3rd Annual Boston Radionuclide Theranostics Forum** which will focus on whether radionuclide theranostics is coming of age and its potential and recent successes as a transformative force in precision oncology:

1. **Supply Chain**
2. **Clinical Development**
3. **Deal Stories: How to Win**

Speakers, panelists and attendees will jointly tackle these three major fields of radionuclide theranostics which will be decisive whether radionuclide theranostics is indeed ready for big business in precision oncology.

ABOUT THE ORGANIZERS

This Forum is initiated and created by **Eckert & Ziegler**, sponsored by **Solomon Partners**, hosted by **Morrison Foerster** and organized with the support of the **German American Business Council of Boston**.

REGISTRATION

The event is by invitation only and is not transferable.

www.EZAG2025.eventbrite.com. Code: EZAG2025



DATE & TIME

Half Day Forum
Thursday, May 29th
8:30AM to 3PM EST



LOCATION

Morrison & Foerster
200 Clarendon Street
Boston, MA 02116

WWW.EZAG2025.EVENTBRITE.COM



CODE:

EZAG2025

Contact: Emily Westhoven, (617) 870-3400
emily.westhoven@gabc-boston.org

3RD BOSTON RADIONUCLIDE THERANOSTICS FORUM

 **Eckert & Ziegler**
Contributing to saving lives

MAY 29TH, 2025
8:30AM TO 3PM

Morrison Foerster
200 Clarendon Street in Boston

THERANOSTICS IS COMING OF AGE IN PRECISION ONCOLOGY

AGENDA

8:30AM	Registration Coffee & Pastries	
9:00AM	Welcome	<ul style="list-style-type: none"> • Matt Karlyn, Partner, Morrison Foerster • Wolfgang Schönig, Partner, Morrison Foerster • Harald Hasselmann, Chief Executive Officer, Eckert & Ziegler
9:15AM	Panel Discussion Supply Chain	<ul style="list-style-type: none"> • Kevin Haehl, Chief Product Officer, Nusano • Vittorio Puppo, President, BWXT • Colin Story, CEO, Betaglu <p>Moderator: Harald Hasselmann, Chief Executive Officer, Eckert & Ziegler</p>
10:00AM	Keynote RLT Ecosystem M&A Update	<ul style="list-style-type: none"> • Aryeh Sand, Partner, Solomon Partners
10:15AM	Deal Stories <i>Past and anticipated deal activity and must-knows when doing deals in the radiotherapeutic space</i>	<ul style="list-style-type: none"> • Aryeh Sand, Partner, Solomon Partners • Thijs Spoor, CEO, Perspective • Christian Behrenbruch, CEO, Telix <p>Moderator: Matt Karlyn, Partner, Morrison Foerster</p>
11:00AM	<i>Break</i>	
11:15AM	Keynote Advances in Radiopharmaceuticals	<ul style="list-style-type: none"> • Christian Behrenbruch, CEO, Telix
11:30AM	Panel Discussion Clinical Development Challenges and solutions for the clinical development of radiopharmaceuticals	<ul style="list-style-type: none"> • Arjun Balar, SVP Global Clinical Development, Eli Lilly & Co. • Boris Hadaschik, Director Urology, Universitätsklinikum Essen • Anna Karmann, Chief Medical Officer, AdvanCell • Jeevan Virk, Strategy Head RLT Therapeutic Area, Novartis <p>Moderator: Ken Herrmann, Chair, Dept. Nuclear Medicine, Universitätsklinikum Essen</p>
12:30PM	Conclusion Networking Lunch sponsored by Solomon Partners	
1PM to 3PM	<i>Networking & Opportunity for Meetings</i>	